M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
Address: Innovation House
70 Norden Road
Maidenhead
Berkshire SL6 4AY
United Kingdom
Tel: +44 1628 501000
Web: http://www.biogenidec.co.uk/
Biogen Idec uses cutting edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. We are the world’s oldest independent biotechnology company and a Fortune 500 company with more than $5 billion in revenues. Patients worldwide benefit from our products.
That’s one perspective on Biogen Idec, though it is not the only one.
To our patients, we are the trusted source of vital therapies for multiple sclerosis. We also discovered one of the world’s most prescribed treatments for non-Hodgkin’s lymphoma and an effective treatment for rheumatoid arthritis. Our patients count on us not only for medications, but also for a variety of support programs that help them deal with the rigors of living with serious illness.
To our employees, we are an exciting and invigorating place to work, an ambitious and nimble company where courageous innovation is encouraged and expected — not just of scientists but of every employee. Our manufacturing people take pride in our leadership in producing biologics, with more than 100,000 liters of capacity spread across three facilities. Our customer service representatives handle more than 800,000 calls per year, offering straightforward information, assistance and patient services. Across the company, in marketing, sales, quality control and human resources, people are empowered to challenge conventional wisdom and propose better ways of doing things.
To our partners and investors, we are a profitable company with a rich and diverse pipeline. We have the resources, financial strength and vision to successfully discover, develop, manufacture and commercialize new products.
And to our friends, neighbors and the world at large, we are a responsible corporate citizen with robust programs that make our communities better places to live and work and address critical issues like diversity and sustainability.
Biogen Idec is all these companies. We are dedicated to serving all our constituents, because Biogen Idec is in business to make a difference for all those we serve.
Biogen Idec’s products and development strategies cover a wide field of key medical issues. With regard to different therapeutic options, Biogen Idec has its focus on the areas of neurology and inflammatory diseases.
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…